An Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
Enrolling By Invitation
18 years - 99 years
All
Phase
N/A
1 Location
Brief description of study
Open label extension trial of CVL-865 in adults with drug-resistant focal onset seizures to learn how well the investigational drug works and how safe it is for long-term epilepsy treatment. Participants will answer questions; undergo physical-neuro exams; vitals; ECG collection; blood draws; urine collection; questions about the study drug; and complete an eDiary. They will take 25mg BID of CVL-865. Participation will last ~61 weeks, with at ~17 in-clinic visits.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Focal Onset Seizures,Epilepsy
-
Age: 18 years - 99 years
-
Gender: All
Subjects who completed treatment in Trial CVL-865-SZ-001
Updated on
04 Aug 2024.
Study ID: 849620
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
